Previous 10 | Next 10 |
home / stock / mrna / mrna articles
The Nasdaq 100 closed higher by 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could b...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
Merck & Company, Inc. (NYSE: MRK) Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion, reflecting s...
On Monday, Cathie Wood-led Ark Invest made a notable move by selling shares of Coinbase Global Inc (NASDAQ:COIN) amid a surge in Bitcoin (CRYPTO: B...
Moderna Inc (NASDAQ: MRNA) shares are continuing to trade lower Tuesday following Pfizer Inc's (NYSE: PFE) warning about reduced Covid-19 ...
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.&...
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. Ma...
Last week, Novavax Inc (NASDAQ: NVAX) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1...
As the rollout of the updated COVID-19 vaccine progresses, some individuals have been surprised by requests for upfront payments ranging from $150 ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...